Slow Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Slow Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-15,000	Closed	-$231K	–	175
2020 Q1	$231K	Hold	15,000	–	–	0.09%	153
2019 Q4	$515K	Hold	15,000	–	–	0.16%	143
2019 Q3	$112K	Hold	15,000	–	–	0.04%	166
2019 Q2	$195K	Buy	+15,000	New	+$192K	0.08%	166

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Slow Capital's ITCI Position: Q2 2020 in Review

Slow Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2020, closing a stake of 15,000 shares — an estimated $231K sold.

Slow Capital first reported a position in ITCI in Q2 2019 and held it in 4 quarters. The position peaked at $515K in Q4 2019. 149 funds tracked by Wall St. Rank hold ITCI as of Q2 2020.

Slow Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2020 after selling out during the quarter.
Slow Capital sold 15,000 Intra-Cellular Therapies Inc. shares in Q2 2020, an estimated $231K.
Slow Capital first reported a position in Intra-Cellular Therapies Inc. in Q2 2019 and held it in 4 quarters.
Slow Capital's Intra-Cellular Therapies Inc. position peaked at $515K in Q4 2019.
149 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2020.

Based on Slow Capital's 13F filing for Q2 2020, filed 10 Aug 2020.